Two in five practicing physicians are equal parts enthused over and worried about AI in healthcare. That’s the same ratio the American Medical Association turned up the last time it conducted its Physician Sentiment Survey.

A trio of leading voices in cardiology reviewed years of data while considering their proposal. The choice between TAVR and SAVR, they added, should be made on a case-by-case basis.

End-of-life decisions are often anything but easy. AI might be able to help. 

An international cluster of 117 researchers from 50 countries has arrived at a consensus on six principles that, in the team’s considered view, ought to guide the use of AI across healthcare worldwide. 

Standing FDA guidance reflects concern over physicians deferring to AI-aided CDS recommendations when pressed for time or uncertain of their own judgments. Is that stance outdated? 

Benzodiazepines are administered before a majority of cardiac surgeries to lower the risk of intraoperative awareness. At the same time, however, recent studies have suggested they increase the risk of postoperative delirium.

A new post-stroke care pathway from Viz.ai and Medtronic is associated with significant benefits, including higher patient and clinician satisfaction.

More than 100 incidents have been reported so far. The FDA is still evaluating this issue, but the agency wanted to raise awareness as quickly as possible.